Baird analyst Brian Skorney reiterated a Neutral rating and $173.00 price target on Amgen (NASDAQ: AMGN)

The analyst comments "Amgen's updated KRAS lung cancer data continue to look good, although compared to the super-high expectations set by the ASCO data, there is likely some letdown as response rates look modestly worse and durability wasn't fantastic. However, it's rare to see anything like a single-agent ORR of around 50% in a relapsed lung cancer setting."

For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.

Shares of Amgen closed at $199.00 yesterday.